These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33731288)

  • 21. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study.
    Rolff HC; Christensen IJ; Vainer B; Svendsen LB; Eefsen RL; Wilhelmsen M; Lund IK; Høyer-Hansen G; Nielsen HJ; Illemann M;
    Clin Cancer Res; 2016 May; 22(10):2427-34. PubMed ID: 26673797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
    Pavillard V; Charasson V; Laroche-Clary A; Soubeyran I; Robert J
    Anticancer Res; 2004; 24(2B):579-85. PubMed ID: 15160997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
    Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
    Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
    Takahashi S; Sakamoto Y; Denda T; Takashima A; Komatsu Y; Nakamura M; Ohori H; Yamaguchi T; Kobayashi Y; Baba H; Kotake M; Amagai K; Kondo H; Shimada K; Sato A; Yuki S; Okita A; Ouchi K; Komine K; Watanabe M; Morita S; Ishioka C
    Cancer Sci; 2021 Apr; 112(4):1567-1578. PubMed ID: 33548159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
    Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
    Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA binding induces conformational transition within human DNA topoisomerase I in solution.
    Oleinikov V; Sukhanova A; Mochalov K; Ustinova O; Kudelina I; Bronstein I; Nabiev I
    Biopolymers; 2002; 67(6):369-75. PubMed ID: 12209444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs.
    Baglini E; Salerno S; Barresi E; Robello M; Da Settimo F; Taliani S; Marini AM
    Eur J Pharm Sci; 2021 Jan; 156():105594. PubMed ID: 33059042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
    Shen J; Wei J; Wang H; Yue G; Yu L; Yang Y; Xie L; Zou Z; Qian X; Ding Y; Guan W; Liu B
    J Transl Med; 2013 Mar; 11():73. PubMed ID: 23517622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    Palshof JA; Høgdall EV; Poulsen TS; Linnemann D; Jensen BV; Pfeiffer P; Tarpgaard LS; Brünner N; Stenvang J; Yilmaz M; Nielsen DL
    BMC Cancer; 2017 Jan; 17(1):48. PubMed ID: 28077117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective Study of the Predictive Value of Target Now in Systemic Therapy for Metastatic Colorectal and Gastric Carcinomas.
    Cohen JE; Cohen Y; Peretz T; Hubert A
    Isr Med Assoc J; 2015 Oct; 17(10):612-5. PubMed ID: 26665314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
    Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
    Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
    Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
    Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
    Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
    Ouchi K; Takahashi S; Yamada Y; Tsuji S; Tatsuno K; Takahashi H; Takahashi N; Takahashi M; Shimodaira H; Aburatani H; Ishioka C
    Cancer Sci; 2015 Dec; 106(12):1722-9. PubMed ID: 26426205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.